These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8032298)

  • 21. Clearance of complement by human vascular endothelial cells: effects of hypoxia/reoxygenation and IL-1beta activation.
    Haun JB; Baldwin WM; Alevriadou BR
    Transpl Int; 2005 Apr; 18(4):475-82. PubMed ID: 15773971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic complement activation levels in Stargardt disease.
    Dhooge PPA; Runhart EH; Li CHZ; de Kat Angelino CM; Hoyng CB; van der Molen RG; den Hollander AI
    PLoS One; 2021; 16(6):e0253716. PubMed ID: 34170959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking.
    Shaw CD; Storek MJ; Young KA; Kovacs JM; Thurman JM; Holers VM; Hannan JP
    J Mol Biol; 2010 Dec; 404(4):697-710. PubMed ID: 20951140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L; Isenman DE
    J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A flow cytometric immunoassay to quantify adsorption of complement activation products (iC3b, C3d, SC5b-9) on artificial surfaces.
    Gemmell CH
    J Biomed Mater Res; 1997 Dec; 37(4):474-80. PubMed ID: 9407295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
    Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
    J Biol Chem; 2009 Apr; 284(14):9513-20. PubMed ID: 19164292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C3d plasma levels and CD21 expressing B-cells in children after ABO-incompatible heart transplantation: Alterations associated with blood group tolerance.
    Urschel S; Ryan LA; Larsen IM; Derkatz K; Rebeyka IM; Ross DB; West LJ
    J Heart Lung Transplant; 2014 Nov; 33(11):1149-56. PubMed ID: 24954883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous streptokinase.
    Freysdottir J; Ormarsdottir S; Sigfusson A
    Clin Exp Immunol; 1993 Nov; 94(2):286-90. PubMed ID: 8222319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2.
    Griffioen AW; Rijkers GT; Janssens-Korpela P; Zegers BJ
    Infect Immun; 1991 May; 59(5):1839-45. PubMed ID: 1826897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of lutein supplementation on blood plasma levels of complement factor D, C5a and C3d.
    Tian Y; Kijlstra A; van der Veen RL; Makridaki M; Murray IJ; Berendschot TT
    PLoS One; 2013; 8(8):e73387. PubMed ID: 24009749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
    Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
    J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Free radical involvement in hypertrophic scar formation.
    Wan KC; Evans JH
    Free Radic Biol Med; 1999 Mar; 26(5-6):603-8. PubMed ID: 10218648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H.
    Hellwage J; Jokiranta TS; Friese MA; Wolk TU; Kampen E; Zipfel PF; Meri S
    J Immunol; 2002 Dec; 169(12):6935-44. PubMed ID: 12471127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma C3d levels and ischemic heart disease in type II diabetes.
    Figueredo A; Ibarra JL; Bagazgoitia J; Rodriguez A; Molino AM; Fernandez-Cruz A; Patino R
    Diabetes Care; 1993 Feb; 16(2):445-9. PubMed ID: 8432215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant complement receptor 2 radiolabeled with [99mTc(CO)3]+: a potential new radiopharmaceutical for imaging activated complement.
    Badar A; DeFreitas S; McDonnell JM; Yahya N; Thakor D; Razavi R; Smith R; Sacks S; Mullen GE
    PLoS One; 2011 Apr; 6(4):e18275. PubMed ID: 21494666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specificities of monoclonal antibodies against the complement C3d split product.
    Lund ED; Sørensen LS; Brandslund I
    Complement Inflamm; 1990; 7(1):18-29. PubMed ID: 2323184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
    Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
    Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative study of assays detecting complement activation. Complement-split product C3d (rocket immuno-electrophoresis) and C3d neodeterminants (ELISA).
    Espersen GT; Langeland B; Grunnet N
    Scand J Clin Lab Invest; 1990 Jun; 50(4):389-93. PubMed ID: 1697427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel function of complement C3d as an autologous helper T-cell target.
    Knopf PM; Rivera DS; Hai SH; McMurry J; Martin W; De Groot AS
    Immunol Cell Biol; 2008; 86(3):221-5. PubMed ID: 18180801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss.
    Sicard A; Ducreux S; Rabeyrin M; Couzi L; McGregor B; Badet L; Scoazec JY; Bachelet T; Lepreux S; Visentin J; Merville P; Fremeaux-Bacchi V; Morelon E; Taupin JL; Dubois V; Thaunat O
    J Am Soc Nephrol; 2015 Feb; 26(2):457-67. PubMed ID: 25125383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.